Feldmann Georg
Klinik und Poliklinik für Innere Medizin III, CIO Aachen-Bonn-Köln-Düsseldorf, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland.
Internist (Berl). 2020 Feb;61(2):226-232. doi: 10.1007/s00108-020-00750-y.
Pancreatic cancer is among the most fatal of all known human malignancies and novel therapeutic concepts are urgently required.
A brief overview of currently available options for systemic therapy is provided with a focus on new developments in recent years. In addition, an outlook on possible relevant trends for future advancements is given.
Although the systemic treatment of pancreatic cancer remains challenging, in recent years significant progress has been made in cytostatic chemotherapy in palliative as well as adjuvant settings. While immunotherapeutic approaches currently remain restricted to selected individual cases, the systemic molecular genetic characterization and individualized targeted therapeutic approaches are increasingly gaining in importance.
Treatment of pancreatic cancer patients currently remains a domain of cytostatic chemotherapy but novel approaches are emerging that have the potential to revolutionize the therapeutic landscape of pancreatic cancer in the near future.
胰腺癌是所有已知人类恶性肿瘤中致死率最高的疾病之一，迫切需要新的治疗理念。
简要概述目前可用的全身治疗方案，重点关注近年来的新进展。此外，对未来进展可能的相关趋势进行展望。
尽管胰腺癌的全身治疗仍然具有挑战性，但近年来在姑息性和辅助性环境下的细胞毒性化疗方面取得了重大进展。虽然免疫治疗方法目前仍局限于特定个体病例，但全身分子遗传学特征分析和个体化靶向治疗方法正变得越来越重要。
目前胰腺癌患者的治疗仍然是细胞毒性化疗的领域，但新的方法正在出现，有可能在不久的将来彻底改变胰腺癌的治疗格局。
